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ABSTRACT
Background and Objectives: To compare cardiovascular disease (CVD) risk associated with 5 
different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes.
Methods: We identified 534,327 people who were newly prescribed sitagliptin (n=167,157), 
vildagliptin (n=67,412), saxagliptin (n=29,479), linagliptin (n=220,672), or gemigliptin 
(n=49,607) between January 2013 and June 2015 using the claims database of the Korean 
National Health Insurance System. A Cox proportional hazards model was used to estimate 
hazard ratios (HRs) for major CVD events (myocardial infarction, stroke, or death) among 
users of different DPP-4is. The model was adjusted for sex, age, duration of DPP-4i use, use 
of other glucose-lowering drugs, use of antiplatelet agents, hypertension, dyslipidemia, 
atrial fibrillation, chronic kidney disease, microvascular complications of diabetes, Charlson 
comorbidity index, and the calendar index year as potential confounders.
Results: Compared to sitagliptin users, the fully adjusted HRs for CVD events were 0.97 
(95% confidence interval [CI], 0.94–1.01; p=0.163) for vildagliptin, 0.76 (95% CI, 0.71–0.81; 
p<0.001) for saxagliptin, 0.95 (95% CI, 0.92–0.98; p<0.001) for linagliptin, and 0.84 (95% 
CI, 0.80–0.88; p<0.001) for gemigliptin.
Conclusions: Compared to sitagliptin therapy, saxagliptin, linagliptin, and gemigliptin 
therapies were all associated with a lower risk of cardiovascular events.
Keywords: Type 2 diabetes mellitus; Cardiovascular diseases; Dipeptidyl-peptidase IV inhibitors
INTRODUCTION
Type 2 diabetes is a chronic and progressive disease that is an increasing global health 
problem. It has considerable impact on morbidity and mortality, particularly on 
cardiovascular complications.1) To delay or prevent these complications, the management 
of type 2 diabetes through lifestyle modifications and the selection of appropriate glucose-
lowering drugs are necessary.2)
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Dipeptidyl peptidase-4 inhibitors (DPP-4is) are a relatively new class of oral hypoglycemic 
agents for treating type 2 diabetes; their effects are mediated through the incretin hormones, 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). 
Previous studies have suggested that DPP-4i as a monotherapy or in combination with other 
oral hypoglycemic agents has potentially beneficial effects on cardiovascular outcomes.3-6) 
A recent study by Ha et al.,6) based on the 2011–2015 Korean National Health Insurance 
Service (NHIS) database, reported that people with type 2 diabetes who added a DPP-4i as a 
second-line drug to metformin had lower risks of cardiovascular disease (CVD) and all-cause 
mortality, compared to those who added sulfonylurea. However, there are some practical 
differences between the DPP-4is such as duration of action, metabolism, elimination, 
and isolated compound-specific characteristics.7) Although there have been randomized 
controlled trials studying the effects of each DPP-4i on CVD, the results have been 
inconsistent,8-10) and there is little evidence comparing the effects of DPP-4i on CVD using 
large-scale observational studies.11-13)
We conducted a real-world cohort study to compare the CVD risks of different DPP-4is 
among people with type 2 diabetes through an analysis of a nationwide health insurance 
database in Korea.
METHODS
The current analyses were based on a dataset from the NHIS, the compulsory single-
payer national health care coverage system in South Korea. The NHIS claims database 
includes a de-identified research dataset of demographic information, disease diagnoses, 
therapeutic procedures, and drug prescriptions. In addition, the NHIS requires biennial 
health screening tests that include health questionnaire surveys, physical examinations, and 
biochemical test results.
Among people with type 2 diabetes (International Classification of Diseases, 10th Edition 
[ICD-10] codes E11–E14), we selected a subset who were newly prescribed DPP-4is for at least 
90 days between January 2013 and June 2015. DPP-4is were limited to the 5 most common 
drugs: sitagliptin, vildagliptin, saxagliptin, linagliptin, and gemigliptin. The start date of 
medication administration was defined as the index date. We excluded people aged <30 years 
or >90 years at the index date, and/or who had a history of CVD or cancer between the year 
prior to the index date and within 90 days after the index (Figure 1). The outcome was the 
modified major adverse cardiovascular events, defined as hospitalized myocardial infarction 
(ICD-10 codes I21–I23), hospitalized stroke (ICD-10 codes I60–I69), or all-cause death. The 
date of CVD onset was the date of the first occurrence of the event. This study was performed 
as an “intention to treat” analysis. The end of follow-up was the CVD diagnosis or the end of 
the study period (June 30, 2015), or whichever occurred first.
We used Kaplan-Meier analyses to compare cumulative incidence of CVD by the 5 different 
DPP-4is. A Cox proportional hazards model was used to estimate the relationships between 
the 5 different DPP-4is and CVD risk, calculating hazard ratios (HRs) and 95% confidence 
intervals (CIs) and adjusting for potential confounders. Although the NHIS claims database 
included major risk factor variables, there may be some unmeasured confounding factors. 
Therefore, we utilized 2 approaches. First, we conducted the main analysis, including 
the following factors as confounders: sex, age, duration of DPP-4i use, use of other 
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glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), use of 
antiplatelet agents (Anatomical Therapeutic Chemical [ATC] code B01), calendar year, 
Charlson comorbidity index (CCI), and comorbidities.14) The comorbid conditions included 
hypertension (ICD-10 codes I10–I15 and/or ATC codes C02–C03, or C07–C09), dyslipidemia 
(ICD-10 code E78 and/or ATC code C10), atrial fibrillation (ICD-10 code I48), chronic 
kidney disease (ICD-10 code N18), and microvascular complications of diabetes including 
retinopathy (ICD-10 codes E11.3, E12.3, E13.3, E14.3, or H36.0), neuropathy (ICD-10 codes 
E11.4, E12.4, E13.4, E14.4, or G63.2), or nephropathy (ICD-10 codes E11.2, E12.2, E13.2, 
E14.2, or N08.3) within the year prior to the index date. Second, we conducted additional 
analysis only on those who had health screening data collected within the 2 years prior to the 
index date. These analyses included sex, age, duration of DPP-4i use, use of other glucose-
lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), calendar year, body 
mass index (BMI), waist circumference, systolic blood pressure, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting 
glucose, serum creatinine, smoking status (yes or no), family history of stroke and heart 
disease, and CCI. All of the analyses were conducted using SAS software, version 9.4 (SAS 
Institute Inc., Cary, NC, USA).
Ethical consideration
This study used a de-identified dataset that was prepared and monitored by the Korea NHIS. 
The study protocol was reviewed and approved by the Institutional Review Board (IRB) of 
Severance Hospital at Yonsei University College of Medicine (IRB No. 4-2015-1023).
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Approximately 50 million Koreans in
the National Health Insurance Service database
People with type 2 diabetes
from January 1, 2013 to June 30, 2015 (n=3,281,130)
Started on DPP-4i regimen 
from January 1, 2013 to June 30, 2015 (n=661,758)
Sitagliptin
(n=167,157)
Vildagliptin
(n=67,412)
Saxagliptin
(n=29,479)
Linagliptin
(n=220,672)
Gemigliptin
(n=49,607)
Excluded:
• People who didn't received DPP-4i in 2013–2015 (n=1,631,516)
• People who had received DPP-4i in 2011–2012 (n=728,809)
• People who had received DPP-4i regimen <90 days (n=259,047)
Excluded:
• People aged <30 years or >90 years at index date (n=5,808) 
• People with history of CVD or cancer between 1 year before
the index date and within 90 days after the index (n=121,623)
Figure 1. Flow of people through study. 
CVD = cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor.
RESULTS
A total of 534,327 people with type 2 diabetes who were newly prescribed DPP-4is (167,157 
sitagliptin users, 67,412 vildagliptin users, 29,479 saxagliptin users, 220,672 linagliptin users, 
and 49,607 gemigliptin users) were identified. The age and sex distribution of the users of 
each DPP-4i were similar, with a mean age of approximately 60 years; approximately 57.1% 
of the people were male (Table 1). The baseline characteristics of the analysis of the health 
screening data was summarized in Supplementary Table 1.
Table 2 and Figure 2 shows the CVD risk for users of each DPP-4i compared to those treated 
with sitagliptin. In the main analysis, CVD risk was significantly lower in saxagliptin users 
(HR, 0.76; 95% CI, 0.71–0.81; p<0.001), linagliptin users (HR, 0.95; 95% CI, 0.92–0.98; 
p<0.001) and gemigliptin users (HR, 0.84; 95% CI, 0.80–0.88; p<0.001) than in sitagliptin 
users after adjusting for all of the confounding variables. However, vildagliptin users were not 
significantly different from sitagliptin users in terms of CVD risk (HR, 0.97; 95% CI, 0.94–
1.01; p=0.163). In addition, this statistical significance was retained saxagliptin, linagliptin, 
and gemigliptin users in the propensity score-matching analysis (data not shown). There was 
a difference in the significant associations of each events (death, myocardial infarction, and 
stroke) for each DPP-4i use (Supplementary Table 2). Because our analysis defined wash-out 
period as 90 days, we did a further analysis with 180, 270, and 360 days wash-out period. 
And, different wash-out period did not severely influence the association (Supplementary 
Table 3). When we divided subgroup by duration of DPP-4i, saxagliptin and gemigliptin users 
had lower risk of CVD in all groups (Supplementary Table 4).
In the analysis of health screening data, saxagliptin and gemigliptin users had significantly 
lower CVD risk than sitagliptin users after adjusting for sex, age, duration of DPP-4i use, use 
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Table 1. Baseline characteristics by DPP-4is
Sitagliptin 
(n=167,157)
Vildagliptin 
(n=67,412)
Saxagliptin 
(n=29,479)
Linagliptin 
(n=220,672)
Gemigliptin 
(n=49,607) p value
Age (years) 59.1±12.0 59.7±12.1 59.7±11.9 60.2±12.0 60.1±11.9 <0.001
Men 97,754 (58.5) 38,957 (57.8) 16,835 (57.1) 124,053 (56.2) 27,492 (55.4) <0.001
Duration of DPP-4i use (years) 1.0±0.6 1.0±0.7 1.0±0.6 1.1±0.6 0.9±0.6 <0.001
Use of other glucose-lowering drugs
Metformin 106,862 (63.9) 42,231 (62.7) 18,192 (61.7) 139,940 (63.4) 31,573 (63.7) <0.001
Sulfonylurea 93,743 (56.1) 39,432 (58.5) 15,080 (51.2) 131,894 (59.8) 27,268 (55.0) <0.001
Thiazolidinedione 11,236 (6.7) 4,729 (7.0) 2,286 (7.8) 16,281 (7.4) 4,554 (9.2) <0.001
Insulin 16,187 (9.7) 9,027 (13.4) 2,865 (9.7) 21,271 (9.6) 6,132 (12.4) <0.001
Use of antiplatelet agents 10,068 (6.0) 4,977 (7.4) 2,737 (9.3) 13,525 (6.1) 3,276 (6.6) <0.001
Comorbidities
Hypertension 110,088 (65.9) 44,742 (66.4) 19,600 (66.5) 152,464 (69.1) 32,938 (66.4) <0.001
Dyslipidemia 132,600 (79.3) 54,321 (80.6) 24,350 (82.6) 178,145 (80.7) 40,150 (80.9) <0.001
Atrial fibrillation 3,620 (2.2) 1,803 (2.7) 792 (2.7) 4,903 (2.2) 1,042 (2.1) <0.001
Chronic kidney disease 14,673 (8.8) 7,748 (11.5) 2,964 (10.1) 26,797 (12.1) 5,613 (11.3) <0.001
Diabetic retinopathy 33,078 (19.8) 15,417 (22.9) 6,094 (20.7) 46,351 (21.0) 9,452 (19.1) <0.001
Diabetic neuropathy 26,087 (15.6) 12,576 (18.7) 5,184 (17.6) 37,828 (17.1) 9,440 (19.0) <0.001
Diabetic nephropathy 4,275 (2.6) 2,387 (3.5) 2,048 (7.0) 6,230 (2.8) 1,512 (3.1) <0.001
CCI score (unit) 4.9±2.5 5.2±2.6 5.1±2.5 5.2±2.6 5.2±2.5 <0.001
Inclusion year
2013 73,308 (43.9) 31,480 (46.7) 11,735 (39.8) 114,368 (51.8) 18,245 (36.8)
2014 67,550 (40.4) 24,339 (36.1) 12,156 (41.2) 81,532 (37.0) 21,610 (43.6) <0.001
2015 26,299 (15.7) 11,593 (17.2) 5,588 (19.0) 24,772 (11.2) 9,752 (19.7)
Data are reported as means±standard deviations or numbers (percentages) unless otherwise stated. 
CCI = Charlson comorbidity index; DPP-4i = dipeptidyl peptidase-4 inhibitor.
of other glucose-lowering drugs, calendar year, CCI, BMI, waist circumference, systolic blood 
pressure, blood lipid profile, fasting glucose, serum creatinine, cigarette smoking, and family 
histories of stroke and heart disease, which were measured ≤2 years before DPP-4i therapy 
initiation (saxagliptin users, HR, 0.71; 95% CI, 0.58–0.86; p<0.001; gemigliptin users, HR, 
0.80; 95% CI, 0.69–0.91; p=0.001) (Table 2 and Figure 2).
We repeated the main analysis for subgroups categorized by sex, age, hypertension, 
dyslipidemia, and microvascular complication. Sex, age, microvascular complication 
did not modify the associations. However, when classified as hypertension, saxagliptin, 
linagliptin, and gemigliptin users had significantly lower risk of CVD compare to sitagliptin 
users in people with hypertension. However, this statistical significance was retained 
only saxagliptin users in people without hypertension. When classified as dyslipidemia, 
saxagliptin, linagliptin, and gemigliptin users had significantly lower risk of CVD compare 
to sitagliptin users in people with dyslipidemia. However, this statistical significance was not 
found in people without dyslipidemia (Figure 3). When classified as use of statin, saxagliptin, 
linagliptin, and gemigliptin users had significantly lower risk of CVD compare to sitagliptin 
users regardless of use of statin (data not shown).
DISCUSSION
In this analysis of nationwide real-world data, we observed that the use of saxagliptin, 
linagliptin, or gemigliptin was significantly associated with decreased CVD risk compared to 
sitagliptin use.
Previous studies have reported associations between specific DPP-4i agents and CVD risk. 
A large observational study in the United States demonstrated that new users of sitagliptin 
or saxagliptin had no associated risk for heart failure compared to pioglitazone users.13) 
Based on a large national study using commercially insured claims and an integrated 
laboratory database in the United States, sitagliptin use did not increase the risks of all-
cause hospital admission or death compared to other glucose-lowering agents.15) In a clinical 
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Table 2. HRs for CVD risk among users of different DPP-4is
Number of persons PY Number of events Event rate (per 100,000 PY) Adjusted HR (95% CI) p value
Main analysis*
Sitagliptin 167,157 300,327 8,218 2,736 1.00
Vildagliptin 67,412 121,177 3,700 3,053 0.97 (0.94–1.01) 0.163
Saxagliptin 29,479 50,566 1,151 2,276 0.76 (0.71–0.81) <0.001
Linagliptin 220,672 419,113 11,809 2,818 0.95 (0.92–0.98) <0.001
Gemigliptin 49,607 82,704 2,118 2,561 0.84 (0.80–0.88) <0.001
Analysis of health screening data†
Sitagliptin 22,741 43,127 999 2,316 1.00
Vildagliptin 9,868 18,507 493 2,664 1.06 (0.95–1.18) 0.312
Saxagliptin 3,885 7,010 117 1,669 0.71 (0.58–0.86) <0.001
Linagliptin 30,303 60,099 1,451 2,414 1.00 (0.92–1.08) 0.923
Gemigliptin 6,736 11,665 250 2,143 0.80 (0.69–0.91) 0.001
BMI = body mass index; CCI = Charlson comorbidity index; CI = confidence interval; CVD = cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor; HDL 
= high-density lipoprotein; HR = hazard ratio; LDL = low-density lipoprotein; PY = person-years.
*Adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), use of antiplatelet 
agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, and microvascular complications of diabetes (retinopathy, neuropathy, or 
nephropathy), the CCI score, and calendar index year, †Adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, 
sulfonylurea, thiazolidinedione, or insulin), BMI, waist circumference, systolic blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, 
fasting glucose, serum creatinine level, smoking status, family history of stroke and heart disease, the CCI score, and calendar index year.
trial, using vildagliptin as an add-on medication to metformin resulted in a larger decrease 
in glycosylated hemoglobin than using pioglitazone as an add-on medication (−0.94% 
vs. −0.6%; p=0.010).16) However, real-world data from 5 European electronic healthcare 
databases showed that vildagliptin had no association with CVD compared to other glucose-
lowering agents (range of adjusted incidence rate ratios=0.22–1.02).17) Using the Korean 
Health Insurance Review and Assessment Service database, new users of sitagliptin and 
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No. at risk
Sitagliptin 167,157 164,491 139,425 107,800 72,156 42,190 4,356
Vildagliptin 67,412 66,243 55,030 43,156 30,544 17,819 1,608
Saxagliptin 29,479 29,099 23,885 17,410 11,570 6,357 725
Linagliptin 220,672 217,232 192,784 158,157 112,733 62,689 4,918
Gemigliptin 49,607 48,963 39,714 29,078 19,266 8,904 367
Time (years)
A
0 0.5 1.0 1.5 2.0
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Sitagliptin (Reference)
Vildagliptin (Crude HR=1.11, p<0.001)
Saxagliptin (Crude HR=0.82, p<0.001)
Linagliptin (Crude HR=1.02, p=0.315)
Gemigliptin (Crude HR=0.90, p<0.001)
No. at risk
Sitagliptin 22,741 22,461 19,346 15,724 11,265 7,002 764
Vildagliptin 9,868 9,726 8,165 6,711 4,962 3,059 295
Saxagliptin 3,885 3,849 3,212 2,482 1,747 1,000 115
Linagliptin 30,303 29,912 26,893 22,781 17,136 10,201 914
Gemigliptin 6,736 6,657 5,431 4,216 2,822 1,404 53
Time (years)
B
0 0.5 1.0 1.5 2.0
Cu
m
ul
at
iv
e 
in
ci
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(%
)
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8
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2
2.5 3.0
Sitagliptin (Reference)
Vildagliptin (Crude HR=1.15, p=0.013)
Saxagliptin (Crude HR=0.71, p<0.001)
Linagliptin (Crude HR=1.03, p=0.416)
Gemigliptin (Crude HR=0.89, p=0.102)
Figure 2. Cumulative incidence of cardiovascular events by different DPP-4is. (A) Main analysis. (B) Analysis of 
health screening data. 
DPP-4i = dipeptidyl peptidase-4 inhibitor; HR = hazard ratio.
401https://e-kcj.org https://doi.org/10.4070/kcj.2017.0324
Dipeptidyl Peptidase-4 Inhibitors and CVD Risk
PY No. of events HR (95% CI)
Sex
Men
Sitagliptin 175,469 4,534 1.00 (reference)
Vildagliptin 70,192 2,107 0.98 (0.93–1.03)
Saxagliptin 28,870 619 0.73 (0.67–0.80)
Linagliptin 235,336 6,338 0.94 (0.90–0.97)
Gemigliptin 45,835 1,153 0.84 (0.79–0.90)
Women
Sitagliptin 124,858 3,684 1.00 (reference)
Vildagliptin 50,985 1,593 0.94 (0.89–1.00)
Saxagliptin 21,695 532 0.77 (0.71–0.85)
Linagliptin 183,777 5,471 0.94 (0.90–0.98)
Gemigliptin 36,869 965 0.80 (0.74–0.86)
Age groups
<65
Sitagliptin 202,793 2,978 1.00 (reference)
Vildagliptin 79,370 1,288 0.95 (0.89–1.02)
Saxagliptin 33,423 368 0.68 (0.61–0.76)
Linagliptin 270,301 3,838 0.90 (0.86–0.95)
Gemigliptin 53,254 678 0.78 (0.72–0.85)
≥65
Sitagliptin 97,534 5,240 1.00 (reference)
Vildagliptin 41,807 2,412 0.97 (0.92–1.02)
Saxagliptin 17,143 783 0.79 (0.73–0.85)
Linagliptin 148,811 7,971 0.97 (0.93–1.00)
Gemigliptin 29,449 1,440 0.85 (0.80–0.90)
Hypertension
Yes
Sitagliptin 200,564 7,206 1.00 (reference)
Vildagliptin 81,678 3,235 0.96 (0.92–1.00)
Saxagliptin 34,433 1,003 0.75 (0.70–0.80)
Linagliptin 291,095 10,483 0.95 (0.92–0.98)
Gemigliptin 55,893 1,859 0.83 (0.79–0.87)
No
Sitagliptin 99,762 1,012 1.00 (reference)
Vildagliptin 39,499 465 1.04 (0.93–1.16)
Saxagliptin 16,133 148 0.79 (0.66–0.94)
Linagliptin 128,017 1,326 0.96 (0.88–1.04)
Gemigliptin 26,811 259 0.87 (0.76–1.00)
Dyslipidemia
Yes
Sitagliptin 245,306 7,035 1.00 (reference)
Vildagliptin 101,087 3,174 0.97 (0.93–1.01)
Saxagliptin 43,395 996 0.74 (0.69–0.79)
Linagliptin 345,427 10,074 0.94 (0.91–0.97)
Gemigliptin 68,994 1,770 0.81 (0.77–0.85)
No
Sitagliptin 55,021 1,183 1.00 (reference)
Vildagliptin 20,090 526 1.01 (0.91–1.12)
Saxagliptin 7,171 155 0.92 (0.77–1.08)
Linagliptin 73,686 1,735 1.01 (0.94–1.09)
Gemigliptin 13,710 348 1.01 (0.90–1.14)
Microvascular complication
Yes
Sitagliptin 101,436 3,787 1.00 (reference)
Vildagliptin 47,132 1,860 0.97 (0.92–1.02)
Saxagliptin 19,036 568 0.76 (0.69–0.83)
Linagliptin 147,266 5,691 0.95 (0.91–0.99)
Gemigliptin 29,298 1,019 0.84 (0.78–0.90)
No
Sitagliptin 198,891 4,431 1.00 (reference)
Vildagliptin 74,045 1,840 0.97 (0.92–1.02)
Saxagliptin 31,530 583 0.76 (0.70–0.83)
Linagliptin 271,847 6,118 0.95 (0.92–0.99)
Gemigliptin 53,405 1,099 0.83 (0.78–0.89)
0.5 1.51.0
Figure 3. Subgroup analysis by sex, age group, hypertension, dyslipidemia, microvascular complication. These analyses were adjusted to address potential 
confounding by sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), use of antiplatelet 
agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, and microvascular complications of diabetes (retinopathy, neuropathy, or 
nephropathy), the CCI score, and calendar index year. 
CCI = Charlson comorbidity index; CI = confidence interval; DPP-4i = dipeptidyl peptidase-4 inhibitor; HR = hazard ratio; PY = person-years.  
 (continued to the next page)
vildagliptin had no associations with CVD compared to pioglitazone users.12) In a clinical 
trial, linagliptin was associated with significantly lower risk of CVD than sulfonylurea 
glimepiride (relative risk=0.46; p=0.021).18) Gemigliptin demonstrated a protective effect 
against CVD.19) Pooled meta-analyses with DPP-4i (sitagliptin, vildagliptin, saxagliptin, and 
linagliptin) reported significant decreases in cardiovascular events.20-24)
The risk of CVD, particularly heart failure, for DPP-4i users has been controversial in 
randomized controlled trials. The SAVOR-TIMI 53 trial reported that saxagliptin showed 
no significant associations with cardiovascular risks including cardiovascular death, 
nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable 
angina, coronary revascularization, or heart failure compared to a placebo group (HR, 1.02; 
p=0.660). When classified as subtypes of CVD, saxagliptin had a significantly increased 
risk for only heart failure (HR, 1.27; p=0.007), but not for other subtypes of CVD.10) The 
TECOS trial showed that sitagliptin had no significant associations with CVD, comprising 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for 
unstable angina (HR, 0.98; p=0.650); but also heart failure (HR, 1.00; p=0.980).8) However, 
there were no significant differences in CVD risk between saxagliptin users and sitagliptin 
users based on a United States insurance claims database.11)
DPP-4is are glucose-lowering agents that inhibit the metabolism of the incretin hormones GLP-
1 and GIP.25) Experimental and preliminary clinical data have reported that GLP-1 has beneficial 
cardiovascular effects.26)27) Although different DPP-4is act on the human body in similar ways, 
there are some intrinsic pharmacological differences.7) In particular, the differential selectivities 
among DPP-4is for non-GLP-1 substrates may cause a risk of hospitalizations for heart failure.28) 
However, the reasons for the different effects on CVD among the classes of DPP-4i are unclear.
To the best of our knowledge, this study was the first to investigate the associations between 
DPP-4i and cardiovascular risk among people with type 2 diabetes using nationwide real-
world data from Korea. Despite yielding several important findings, this study faced several 
limitations that should be considered when reviewing the results. First, there were potential 
misclassifications of outcomes because we used definitions based on diagnoses from health 
insurance claims data. However, previous validation studies for the identification of CVD events 
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PY No. of events HR (95% CI)
Sex
Men
Sitagliptin 175,469 4,534 1.00 (reference)
Vildagliptin 70,192 2,107 0.98 (0.93–1.03)
Saxagliptin 28,870 619 0.73 (0.67–0.80)
Linagliptin 235,336 6,338 0.94 (0.90–0.97)
Gemigliptin 45,835 1,153 0.84 (0.79–0.90)
Women
Sitagliptin 124,858 3,684 1.00 (reference)
Vildagliptin 50,985 1,593 0.94 (0.89–1.00)
Saxagliptin 21,695 532 0.77 (0.71–0.85)
Linagliptin 183,777 5,471 0.94 (0.90–0.98)
Gemigliptin 36,869 965 0.80 (0.74–0.86)
Age groups
<65
Sitagliptin 202,793 2,978 1.00 (reference)
Vildagliptin 79,370 1,288 0.95 (0.89–1.02)
Saxagliptin 33,423 368 0.68 (0.61–0.76)
Linagliptin 270,301 3,838 0.90 (0.86–0.95)
Gemigliptin 53,254 678 0.78 (0.72–0.85)
≥65
Sitagliptin 97,534 5,240 1.00 (reference)
Vildagliptin 41,807 2,412 0.97 (0.92–1.02)
Saxagliptin 17,143 783 0.79 (0.73–0.85)
Linagliptin 148,811 7,971 0.97 (0.93–1.00)
Gemigliptin 29,449 1,440 0.85 (0.80–0.90)
Hypertension
Yes
Sitagliptin 200,564 7,206 1.00 (reference)
Vildagliptin 81,678 3,235 0.96 (0.92–1.00)
Saxagliptin 34,433 1,003 0.75 (0.70–0.80)
Linagliptin 291,095 10,483 0.95 (0.92–0.98)
Gemigliptin 55,893 1,859 0.83 (0.79–0.87)
No
Sitagliptin 99,762 1,012 1.00 (reference)
Vildagliptin 39,499 465 1.04 (0.93–1.16)
Saxagliptin 16,133 148 0.79 (0.66–0.94)
Linagliptin 128,017 1,326 0.96 (0.88–1.04)
Gemigliptin 26,811 259 0.87 (0.76–1.00)
Dyslipidemia
Yes
Sitagliptin 245,306 7,035 1.00 (reference)
Vildagliptin 101,087 3,174 0.97 (0.93–1.01)
Saxagliptin 43,395 996 0.74 (0.69–0.79)
Linagliptin 345,427 10,074 0.94 (0.91–0.97)
Gemigliptin 68,994 1,770 0.81 (0.77–0.85)
No
Sitagliptin 55,021 1,183 1.00 (reference)
Vildagliptin 20,090 526 1.01 (0.91–1.12)
Saxagliptin 7,171 155 0.92 (0.77–1.08)
Linagliptin 73,686 1,735 1.01 (0.94–1.09)
Gemigliptin 13,710 348 1.01 (0.90–1.14)
Microvascular complication
Yes
Sitagliptin 101,436 3,787 1.00 (reference)
Vildagliptin 47,132 1,860 0.97 (0.92–1.02)
Saxagliptin 19,036 568 0.76 (0.69–0.83)
Linagliptin 147,266 5,691 0.95 (0.91–0.99)
Gemigliptin 29,298 1,019 0.84 (0.78–0.90)
No
Sitagliptin 198,891 4,431 1.00 (reference)
Vildagliptin 74,045 1,840 0.97 (0.92–1.02)
Saxagliptin 31,530 583 0.76 (0.70–0.83)
Linagliptin 271,847 6,118 0.95 (0.92–0.99)
Gemigliptin 53,405 1,099 0.83 (0.78–0.89)
0.5 1.51.0
Figure 3. (Continued) Subgroup analysis by sex, age group, hypertension, dyslipidemia, microvascular complication. These analyses were adjusted to address 
potential confounding by sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), use of 
antiplatelet agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, and microvascular complications of diabetes (retinopathy, neuropathy, 
or nephropathy), the CCI score, and calendar index year. 
CCI = Charlson comorbidity index; CI = confidence interval; DPP-4i = dipeptidyl peptidase-4 inhibitor; HR = hazard ratio; PY = person-years.
showed 71.4% for myocardial infarction and 83.4% for ischemic stroke.29)30) Second, as the mean 
follow-up period was relatively short, additional studies are needed to compare the long-term 
effects of the different DPP-4i. Finally, we cannot exclude the possibility of residual confounding 
by unmeasured or uncontrolled confounders such as duration of diabetes, time-varying 
confounders because this is an observational study using a health insurance claims database. 
Although the analysis of health screening data adjusting for clinical variables attenuate this 
concern, we still cannot completely rule out the possibility of residual confounding.
In conclusion, this analysis of nationwide real-world data from Korea suggests that compared 
to sitagliptin use, saxagliptin, linagliptin, and gemigliptin use was associated with a lower 
risk of cardiovascular events. Further large-scale observational studies evaluating the 
differences among DPP-4is in terms of cardiovascular benefits or risks are needed.
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